|
|
|
|
| LEADER |
02627nam a2200625Ia 4500 |
| 001 |
10.4155-bio-2021-0201 |
| 008 |
220427s2021 CNT 000 0 und d |
| 020 |
|
|
|a 17576180 (ISSN)
|
| 245 |
1 |
0 |
|a With great power comes great responsibility: High-dimensional spectral flow cytometry to support clinical trials
|
| 260 |
|
0 |
|b Future Medicine Ltd.
|c 2021
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.4155/bio-2021-0201
|
| 520 |
3 |
|
|a Flow cytometry is a powerful technology used in research, drug development and clinical sample analysis for cell identification and characterization, allowing for the simultaneous interrogation of multiple targets on various cell subsets from limited samples. Recent advancements in instrumentation and fluorochrome availability have resulted in significant increases in the complexity and dimensionality of flow cytometry panels. Though this increase in panel size allows for detection of a broader range of markers and sub-populations, even in restricted biological samples, it also comes with many challenges in panel design, optimization, and downstream data analysis and interpretation. In the current paper we describe the practices we established for development of high-dimensional panels on the Aurora spectral flow cytometer to aid clinical sample analysis. © 2021 Newlands Press.
|
| 650 |
0 |
4 |
|a analytic method
|
| 650 |
0 |
4 |
|a antibody detection
|
| 650 |
0 |
4 |
|a antibody titer
|
| 650 |
0 |
4 |
|a antibody titration
|
| 650 |
0 |
4 |
|a Article
|
| 650 |
0 |
4 |
|a Aurora
|
| 650 |
0 |
4 |
|a B lymphocyte
|
| 650 |
0 |
4 |
|a biomarkers
|
| 650 |
0 |
4 |
|a cell function
|
| 650 |
0 |
4 |
|a clinical feature
|
| 650 |
0 |
4 |
|a clinical practice
|
| 650 |
0 |
4 |
|a clinical study
|
| 650 |
0 |
4 |
|a clinical trial (topic)
|
| 650 |
0 |
4 |
|a Clinical Trials as Topic
|
| 650 |
0 |
4 |
|a CSI
|
| 650 |
0 |
4 |
|a data analysis
|
| 650 |
0 |
4 |
|a flow cytometry
|
| 650 |
0 |
4 |
|a flow cytometry
|
| 650 |
0 |
4 |
|a Flow Cytometry
|
| 650 |
0 |
4 |
|a flow rate
|
| 650 |
0 |
4 |
|a fluorochromes
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a instrument validation
|
| 650 |
0 |
4 |
|a natural killer cell
|
| 650 |
0 |
4 |
|a panel study
|
| 650 |
0 |
4 |
|a process technology
|
| 650 |
0 |
4 |
|a program development
|
| 650 |
0 |
4 |
|a reference value
|
| 650 |
0 |
4 |
|a SFCM
|
| 650 |
0 |
4 |
|a software
|
| 650 |
0 |
4 |
|a spectral flow cytometry
|
| 650 |
0 |
4 |
|a SSM
|
| 650 |
0 |
4 |
|a standardization
|
| 650 |
0 |
4 |
|a T lymphocyte
|
| 650 |
0 |
4 |
|a validation
|
| 650 |
0 |
4 |
|a viscosity
|
| 700 |
1 |
|
|a Decman, V.
|e author
|
| 700 |
1 |
|
|a Groves, C.
|e author
|
| 700 |
1 |
|
|a Lin, Y.-D.
|e author
|
| 700 |
1 |
|
|a McCausland, M.
|e author
|
| 700 |
1 |
|
|a Nevers, T.
|e author
|
| 773 |
|
|
|t Bioanalysis
|
